Unknown PHASE4 INTERVENTIONAL 4-arm NCT02612870

Sienna+® Injection Time Study 4 Arms (Sentimag02)

Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Breast Neoplasms

Interventions Sienna+ peri Sienna+ peri 4-6 Sienna+ retro Sienna+ retro 4-6 Technetium 1

Updated 8 times since 2017 Last updated: Nov 23, 2015 Started: Feb 29, 2016 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02612870, this PHASE4 trial focuses on Breast Neoplasms and remains ongoing. Sponsored by Insel Gruppe AG, University Hospital Bern, it has been updated 8 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2021 — Jul 2023 [monthly]

Unknown Status PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insel Gruppe AG, University Hospital Bern
Kantonsspital Baden

Data source: Kantonsspital Baden

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baden, Switzerland
• Bern, Switzerland